Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ON long-term open-label BI 1015550 in IPF and PPF
jRCT2021240008Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of nerandomilast in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Any adverse event over course of extension trial. Started Sep 2024; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on jRCT2021240008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240008.